Injectable Pharmaceutical Composition for Pain Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pain management treatments often fail to effectively address severe and chronic pain, leading to significant limitations in patients' quality of life due to the individual nature of disease profiles and the need for long-term, non-systematic trials of multiple medications with limited improvement.
Innovation Solution
A pharmaceutical composition comprising a pharmaceutically acceptable solvent, diclofenac or lornoxicam, metamizole or tramadol, and a benzodiazepine, administered injectably or infusably, which combines synergistic effects to target multiple pain causes, reducing the need for multiple medications and improving pain relief rapidly.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multiple different pain-alleviating drugs are examined in long-term treatment programs, then the individual disease profile may be addressed, but the treatment process becomes complex and time-consuming with limited improvement
Solution Approach 1:
The patent combines multiple pain-alleviating drugs (NSAIDs, opioids, and adjuvants) into a single fixed-compression formulation that can be administered together. This merging approach maintains the ability to address individual disease profiles while simplifying the treatment process from multiple separate medications to one unified composition, directly reducing treatment program complexity.
Solution Approach 2:
The fixed-compression formulation is designed to be universally applicable to various pain types and individual disease profiles through a standardized combination of drug classes. This multi-functional approach allows a single formulation to address different pain mechanisms (inflammatory, neuropathic, opioid-dependent) without requiring customized treatment programs for each patient.
2Adaptability or versatility
If multiple different pain-alleviating drugs are examined in long-term treatment programs, then the individual disease profile may be addressed, but the treatment duration becomes extended with limited improvement
Solution Approach 1:
By merging multiple drug classes with different mechanisms of action into a single fixed-compression formulation, the patent enables simultaneous targeting of multiple pain pathways. This combination approach accelerates pain relief by addressing inflammatory, neuropathic, and opioid-dependent mechanisms concurrently, reducing the time required to achieve effective pain management compared to sequential trial of individual drugs.
Solution Approach 2:
The fixed-compression formulation is pre-configured with a standardized combination of drugs that addresses multiple pain mechanisms from the outset. This preliminary preparation of a comprehensive treatment regimen eliminates the need for time-consuming sequential trials of individual medications, as the formulation is designed to provide broad-spectrum pain relief from the first administration.
3Reliability
If conventional pain treatments are used, then pain relief may be achieved, but side effects increase and quality of life remains limited
Solution Approach 1:
The patent optimizes the parameter composition of the fixed-compression formulation by carefully selecting specific dosages and combinations of drug classes. This parameter optimization aims to achieve effective pain relief while minimizing side effects through balanced formulation, particularly in managing opioid-dependent pain mechanisms and reducing the need for high-dose single-agent therapy that causes adverse effects.
Data Source
AI summary
The present invention discloses a pharmaceutical composition, wherein the pharmaceutical composition is an injectable or infusable pharmaceutical composition, the pharmaceutical composition comprising:a) a pharmaceutically acceptable solvent,b) a first compound comprising diclofenac and/or lornoxicam or a pharmaceutically acceptable salt or solvate thereof,c) a second compound comprising metamizole or tramadol or a pharmaceutically acceptable salt or solvate thereof, andd) a third compound selected as at least one benzodiazepine or a pharmaceutically acceptable salt or solvate thereof,the pharmaceutical composition further comprising a cortisone derivative or a pharmaceutically acceptable salt or solvate thereof.